The role of the fibronectin receptor, a 5 b 1 -integrin, as an adhesion receptor and in angiogenesis is well established. However, its role in cancer cell invasion and metastasis is less clear. We describe a novel mechanism by which fibronectin regulates ovarian cancer cell signaling and promotes metastasis. Fibronectin binding to a 5 b 1 -integrin led to a direct association of a 5 -integrin with the receptor tyrosine kinase, c-Met, activating it in a hepatocyte growth factor/scatter factor (HGF/SF) independent manner. Subsequently, c-Met associated with Src, and activated Src and focal adhesion kinase (FAK). Inhibition of a 5 b 1 -integrin decreased the phosphorylation of c-Met, FAK and Src, both in vitro and in vivo. Independent activation of c-Met by its native ligand, HGF/SF, or overexpression of a constitutively active FAK in HeyA8 cells could overcome the effect of a 5 b 1 -integrin inhibition on tumor cell invasion, indicating that a 5 b 1 -integrin is upstream of c-Met, Src and FAK. Inhibition of a 5 b 1 -integrin on cancer cells in two xenograft models of ovarian cancer metastasis resulted in a significant decrease of tumor burden, which was independent of the effect of a 5 b 1 -integrin on angiogenesis. These data suggest that fibronectin promotes ovarian cancer invasion and metastasis through an a 5 b 1 -integrin/c-Met/FAK/Src-dependent signaling pathway, transducing signals through c-Met in an HGF/ SF-independent manner.
Introduction
Ovarian cancer is the fifth leading cause of cancerrelated death among women in the United States and has the highest mortality rate of all gynecologic malignancies (Jemal et al., 2009) . It involves a unique metastatic process, which rarely takes the hematogenous route commonly observed in other cancers. The cancer cells exfoliate from the surface of the ovary by shedding from the primary tumor or through hydroflotation caused by circulating peritoneal fluid. They subsequently attach to the peritoneal surfaces and invade to form metastatic tumors. This mode of metastasis places unique demands on the ovarian cancer cells and may require a specific molecular mechanism different from the intra-and extravasation involved in hematogenous metastasis (Lengyel, 2010) .
Integrins are among the genes reported to be involved in ovarian cancer metastasis. They are heterodimeric transmembrane proteins comprised of various combinations of an a-and b-subunit, with each heterodimer possessing one or more ligands (Hynes, 2002) . Integrins anchor the cancer cells to the extracellular matrix (ECM), which provides a contact point for invasion and metastasis. Signals from the ECM are transmitted via integrins through interactions with multiple proteins that eventually determine the cellular response to the ECM, including changes in cell shape, motility, proliferation and so on (Giancotti and Tarone, 2003; Mitra and Schlaepfer, 2006) . The fibronectin receptor (a 5 b 1 -integrin) primarily binds fibronectin to anchor cells and subsequently activates the non-receptor tyrosine kinases (RTKs), focal adhesion kinase (FAK) and Src, which play an important role in tumorigenesis by promoting the proliferation and invasion of cancer and endothelial cells (Mitra and Schlaepfer, 2006; Caswell et al., 2007) .
Knocking out a 5 b 1 -integrin is associated with major vascular defects, such as a marked decrease in capillary branching and incompletely formed vessels in mouse embryos, leading to embryonic lethality (Yang et al., 1993; Francis et al., 2002) . As a 5 b 1 -integrin is abundantly present on endothelial cells, research on this integrin has primarily focused on its role in angiogenesis and elucidated its function in vascular endothelial cells (Kim et al., 2000; Taverna and Hynes, 2001; Magnussen et al., 2005) . Endothelial cells in tumor vessels overexpress a 5 b 1 -integrin, which helps to anchor them to the basement membrane. When antibodies against a 5 b 1 -integrin are injected intravenously, they rapidly label tumor vessels , highlighting the importance of a 5 b 1 -integrin for tumor vasculature. However, the role of a 5 b 1 -integrin, when expressed on tumor cells, is less well understood. We have previously shown that, during ovarian cancer progression, loss of E-cadherin-upregulated a 5 b 1 -integrin, which promoted the adhesion and invasion of ovarian cancer cells. Overexpression of a 5 b 1 -integrin indicated a very poor prognosis in patients with epithelial ovarian cancer . However, the molecular mechanism by which a 5 b 1 -integrin promotes cancer cell metastasis is currently unknown. Given that fibronectin is one of the most abundant proteins in the ECM of both the peritoneum and omentum (Kenny and Lengyel, 2009; Hafter et al., 1984; Franke et al., 2003) , an understanding of how fibronectin-a 5 b 1 -integrin interactions regulate metastasis in the ovarian cancer cell might provide additional insights into the biology of ovarian cancer.
In the present study, we show that upon binding to fibronectin, a 5 b 1 -integrin interacts directly with the receptor tyrosine kinase c-Met, thereby, activating Src and FAK. This is the first report to demonstrate that the fibronectin receptor transduces signals through c-Met, which is itself a major player in ovarian cancer metastasis.
Results
Inhibition of a 5 b 1 -integrin inhibits ovarian cancer metastasis The ECM of the normal human omentum, the most common site of ovarian cancer metastasis, expresses abundant fibronectin and vitronectin (Supplementary Figure S1 ). We and others have previously shown that the fibronectin receptor, a 5 b 1 -integrin, is upregulated in ovarian cancer cells during tumor progression (Yokoyama et al., 2007; Sawada et al., 2008) . Therefore, we decided to inhibit a 5 b 1 -integrin to determine whether this would result in a reduction of ovarian cancer dissemination. Two orthotopic xenograft models of ovarian cancer metastasis were treated with a monoclonal antibody blocking human a 5 b 1 -integrin (Hu a 5 Ab) (Bhaskar et al., 2007) . SKOV3ip1 or HeyA8 human ovarian cancer cells, both of which have high expression levels of a 5 b 1 -integrin (Supplementary Figure S2) , were injected intraperitoneally into nude mice. Although SKOV3ip1 cells form many small metastases, mimicking miliarydisseminated ovarian cancer, HeyA8 cells form a few, large metastases in the omentum and mesentery that resemble the more solid tumor growth found in a subgroup of patients. Tumors were counted, resected and the tumor weight measured. Treatment with the human a 5 b 1 -integrin-blocking antibody reduced tumor weight in HeyA8 and SKOV3ip1 xenografts by 64% (Po0.001) and 73% (Po0.001), respectively, compared with isotype control treatment (Figures 1a and b) . In the SKOV3ip1 model, there was also a 57% (Po0.005) decrease in the number of metastases (Figure 1b) . These mice also produced smaller tumors than the controls, a finding which was paralleled by reduced Ki-67 staining, suggesting a lower proliferation rate upon treatment with the a 5 -integrin antibody (Figure 1b  right panel) .
Currently, the most completely characterized function of a 5 b 1 -integrin in cancer is its contribution to angiogenesis (Wingerter et al., 2005; Avraamides et al., 2008) . However, the human a 5 -integrin antibody used in Figures 1a and b does not cross-react with murine a 5 b 1 -integrin (Bhaskar et al., 2007) , indicating that the effects seen on metastasis and tumor growth are the result of a direct effect of the antibody on the human tumor cells rather than the blocking of host a 5 b 1 -integrin function. To compare the contribution of a 5 b 1 -integrin in cancer cells with that in host stromal cells, we took advantage of an anti-murine a 5 Ab that inhibits angiogenesis by blocking a 5 b 1 -integrin on mouse vascular endothelial cells (Bhaskar et al., 2007) . The specificity of the human and murine a 5 -integrin antibody was confirmed by testing their effect on adhesion of the human ovarian cancer cell line HeyA8 and the mouse ovarian cancer cell line ID-8 on fibronectin (Supplementary Figure S3) . Treatment with the human or the murine a 5 -integrin antibody showed a comparable reduction in tumor weight (57 and 48%, respectively) and numbers (73 and 64%, respectively) in a SKOV3ip xenograft model ( Figure 1c ). This reduction was similar to the effect of bevacizumab (Avastin, Genentech, South San Francisco, CA, USA), a humanized anti-VEGF antibody. Combining the human and murine a 5 b 1 -integrin antibodies did not significantly augment the antitumor effect of each individual antibody (Figure 1c ). Immunohistochemical staining of the tumors for CD31 confirmed an antiangiogenic effect of murine a 5 Ab and bevacizumab, whereas, as expected, the human antibody had no effect on blood vessel density (Supplementary Figure S4) or on VEGF expression (data not shown).
Next, we sought to determine whether a 5 b 1 -integrin plays a more important role in early or in late metastasis (Figure 1d ). To study early metastasis, a single treatment of the integrin antibody was given to the nude mice simultaneously with the intraperitoneal injection of ovarian cancer cells to block the initial attachment and invasion of tumor cells to the peritoneum (prevention study). Late metastasis was studied with the administration of repeated treatments beginning 8 days after the tumors had established within the peritoneal cavity (intervention study). Interestingly, both prevention and intervention studies resulted in similar reductions in tumor weight and the number of metastases, (Figure 1d ). Given that in vitro, the human a 5 -integrin antibody inhibited both ovarian cancer cell adhesion and proliferation (Supplementary Figure S5) , our results suggest that a 5 b 1 -integrin is important for both the initial attachment/invasion and subsequent tumor growth of ovarian cancer cells. Repeating the prevention experiment described above with murine a 5 Ab, expectedly, did not alter metastasis or tumor growth (Figure 1e ).
Based on these results, we performed a survival study after intraperitoneal injection of SKOV3ip1 by administering the a 5 b 1 -integrin antibody or control immunoglobulin G (IgG) twice a week. The median survival was 39 days in the control-treated animals and 56 days when the fibronectin receptor was inhibited (log rank: Po0.0001, Figure 1f ). activates RTKs (Vuori and Ruoslahti 1994; Wang et al., 1996; Nakamura et al., 2008; Ricono et al., 2009) . We and others have previously reported that c-Met contributes to the dissemination of ovarian cancer cells (Saga et al., 2001; Wong et al., 2004; Sawada et al., 2007) , which is why we investigated the interesting possibility that fibronectin-mediated activation of a 5 b 1 -integrin recruits c-Met signaling. To determine whether cell adhesion to fibronectin influences c-Met activation, HeyA8 cells, which express both a 5 b 1 -integrin and c-Met, were transfected with a small interfering RNA (siRNA) against a 5 -integrin and plated on fibronectin.
After 24 h, c-Met was detected by immunoblotting. Silencing a 5 -integrin resulted in decreased phosphorylation of c-Met in the activation loop of the tyrosine kinase domain (Tyr 1230 (Tyr ,1234 (Tyr ,1235 ), but total c-Met expression was unchanged ( Figure 2a To understand the functional significance of a 5 b 1 -integrin signaling through c-Met, invasion assays were performed. HeyA8 cells were transfected with an siRNA against c-Met or a 5 -integrin, and then compared with HeyA8 cells treated with the human a 5 b 1 -integrin antibody. After verifying silencing, we found that the a 5 -integrin and the c-Met siRNA reduced invasion by 89 and 91%, respectively (Figure 3a) . Blocking the fibronectin receptor with a 5 b 1 -integrin antibody had a similar inhibitory effect (87%). There was no additional reduction of invasion when both a 5 b 1 -integrin and c-Met inhibition were combined, suggesting that both are part of the same pathway. The absence of any additive effect was also confirmed at lower concentrations of c-Met siRNA and the human a 5 -integrin antibody (Supplementary Figure S6) . Importantly, the inhibition of invasion by the antibody could be reversed by activating c-Met with its ligand hepatocyte growth factor/scatter factor (HGF/SF) (Figure 3b ). This supports the concept that a 5 b 1 -integrin is upstream of the c-Met receptor, but that c-Met can still be activated independently of a 5 b 1 -integrin by its ligand HGF/SF. a 5 b 1 -Integrin activates a c-Met/FAK/Src signaling pathway Having shown that a 5 b 1 -integrin associates with and activates c-Met, we next sought to identify downstream signaling pathways. Initial experiments focused on the MAPK, STAT-3 and AKT pathways by measuring their key signaling proteins. However, none of these pathways were affected by a 5 b 1 -integrin inhibition (Supplementary Figure S7 and data not shown). Given previous reports that integrins use FAK and Src for signaling, we turned our attention to these non-RTKs (Mitra and Schlaepfer, 2006) . Indeed, blocking a 5 b 1 -integrin with the antibody in HeyA8 cells plated on fibronectin decreased FAK phosphorylation at Tyr 397 , which is the FAK autophosphorylation site, and at Tyr 861 , which is the Src phosphorylation site (Figure 4a ). This was confirmed when a 5 -integrin was silenced with a siRNA (Figure 4a , lower panel) and also confirmed in the SKOV3ip1 ovarian cancer cell line (Supplementary Figure S8a) . Ectopic expression of a constitutively active, membrane-bound form of FAK, CD2-FAK (Chan et al., 1994; Huttenlocher et al., 1998) , reversed, at least in part, the inhibitory effect of the a 5 b 1 -integrin on invasion, whereas neither the mutated CD2-FAK (Y397F) plasmid nor the empty vector (CD2) had any effect (Figure 4b and Supplementary Figure S8b , which is a Src phosphorylation site (Mitra and Schlaepfer, 2006) , we determined whether blocking a 5 b 1 -integrin also inhibits Src phosphorylation and, indeed, found decreased Src phosphorylation after antibody treatment (Figure 4c ).
Although these experiments suggest that a 5 b 1 -integrin regulates FAK and Src, they do not indicate whether these two proteins are downstream of a 5 -integrin or cMet. Both these interactions have been previously reported Mitra and Schlaepfer, 2006; Jin et al., 2007) . First, we tested whether a 5 b 1 -integrin interacted with FAK and/or Src when HeyA8 cells were plated on fibronectin but neither immunoprecipitation nor confocal microscopy showed any interaction (data not shown). Next, we tested whether 
Discussion
The ECM protein, fibronectin, is a potent mediator of cell adhesion, migration and growth. It is also one of the most abundant ECMs and basement membrane proteins in human omentum and peritoneum ( (Franke et al., 2003) and Supplementary Figure S1 ), the most common sites of ovarian cancer metastasis. Our data provide evidence for a novel mechanism by which fibronectin regulates ovarian cancer cell signaling. Binding of a 5 b 1 -integrin to fibronectin recruits the RTK, c-Met, which then activates downstream signaling events. The presence of this mechanism is supported by experiments showing that inhibition of a 5 b 1 -integrin using a siRNA Immunoprecipitation and visualization of c-Met and a 5 -integrin using confocal microscopy imply that the adhesion receptor and the RTK associate to form a molecular signaling unit. Inhibition of a 5 b 1 -integrin also led to a decrease in phosphorylation of c-Met in human umbilical vein endothelial cells, indicating that this process is not specific for cancer cells alone.
The first evidence that adhesion can regulate c-Met came from an observation in the Bishop Laboratory (Wang et al., 1996) at UCSF, showing that adherence of cancer cells to fibronectin and type IV collagen induces phosphorylation of c-Met. This observation was consistent with an inverse experiment using melanoma cancer cells, which showed that the constitutive activation of c-Met is lost upon cellular detachment (Rusciano et al., 1996) . The data presented in our study indicate that cell adhesion regulates c-Met through direct activation by a 5 b 1 -integrin. When a 5 b 1 -integrinmediated c-Met activation was blocked, c-Met could still be stimulated by its ligand, HGF/SF, suggesting that in ovarian cancer cells, c-Met can be activated both in a ligand-dependent and -independent manner. The ligand-dependent activation triggers the canonical pathways involving Erk and AKT (Birchmeier et al., 2003) , which we and others have shown to be inhibited by small molecule inhibitors of c-Met (Birchmeier et al., 2003; Zillhardt et al., 2010) . Fibronectin-mediated activation resulted in signaling via an alternate pathway involving Src and FAK. The cell, therefore, has the flexibility to use the ECM as well as paracrine HGF/SF to gain access to c-Met-directed signaling pathways. However, although c-Met is the signal mediator after a 5 b 1 -integrin activation, it can also initiate integrinmediated signaling. Activation of c-Met leads to association with the a 6 b 4 -integrin and tyrosine phosphorylation of the b 4 -integrin cytoplasmic domain (Trusolino et al., 2001) . In this case, the integrin does not act as the adhesion receptor, but rather as a mediator of c-Met signaling.
To determine whether inhibition of the fibronectin receptor on cancer cells plays a role in either early or late tumor metastasis, ovarian cancer cells received either a single pretreatment with the a 5 b 1 -integrin antibody before intraperitoneal injection (prevention) or were treated repeatedly after solid tumors were established within the peritoneal cavity (intervention). The results indicated that there are at least two distinct mechanisms by which the a 5 b 1 -integrin expression on tumor cells promotes ovarian cancer metastasis. It contributes to the initial adhesion/invasion on the fibronectin-rich peritoneum and omentum, and it later helps the cancer cells to metastasize and proliferate as the tumor progresses. In contrast, host a 5 b 1 -integrin contributes to tumor angiogenesis essential for later stages of metastasis (Kim et al., 2000; Magnussen et al., 2005) .
The integrin-mediated activation of Src and FAK is not a consequence of direct binding of these non-RTKs to the integrin, but occurs via c-Met. Expression of an activated form of FAK was able to overcome the inhibitory function of the a 5 -integrin-blocking antibody These results were confirmed in vivo, as treatment with the human a 5 b 1 -integrin antibody blocked both FAK and Src activation in the tumor. We were never able to show a direct interaction between a 5 -integrin and FAK or Src (data not shown), despite reports that FAK can directly interact with integrins (Mitra and Schlaepfer, 2006) . However, activation of c-Met by a 5 b 1 -integrin resulted in the direct binding of Src to c-Met (but not FAK). This suggests that upon binding to fibronectin, a 5 b 1 -integrin activates c-Met, which then associates with Src and subsequently activates FAK. Consistent with our results, Chen and colleagues reported that when cMet is constitutively activated in aggressive lung cancer cells, FAK interacts with c-Met independent of stimulation with HGF/SF. This was not observed in less invasive cells . It is possible that most of what is seen as the ligand-independent activation of c-Met is instead the regulation of c-Met by a 5 b 1 -integrin.Taking into consideration that c-Met can be activated in a ligand-dependent as well as in a ligandindependent manner, current strategies to inhibit c-Met could be reconsidered: inhibition of the c-Met cytoplasmic domains (for example, the kinase domain) could be more effective than targeting the HGF ligandbinding site. In summary, we define a signaling pathway in ovarian cancer that starts with the fibronectin-mediated activation of a 5 b 1 -integrin and leads to direct contact with c-Met, followed by Src and FAK activation, linking mitogenic RTK signaling with adhesion ( Figure 6 ). This may be one of the mechanisms utilized by cancer cells to constitutively activate c-Met in a fibronectin-rich microenvironment. In particular, this mechanism could be of special importance in ovarian cancer because the first step of ovarian cancer metastasis begins with cancer a 5 b 1 -integrin and c-Met in ovarian cancer AK Mitra et al cell adhesion. Indeed, it could provide an explanation for how, in ovarian cancer, the early adhesion of cancer cells to the fibronectin-rich basement membranes instantly activates key mitogenic-signaling pathways in the cell, allowing a single ovarian cancer cell or a small cluster of cells to survive, invade and subsequently thrive in the initially hostile environment on the surface of the abdominal cavity. , phospho-ERK1/2, ERK1/2, phospho-JNK, JNK, phosphop38 MAPK and p38 MAPK were from Cell Signaling (Danvers, MA, USA). The fibronectin antibody was from Sigma-Aldrich (St Louis, MO, USA); Ki-67 antibody was from LabVision (Fremont, CA, USA); vimentin, collagen IV and laminin antibodies were from Dako Cytomation (Carpinteria, CA, USA). The 5-chloromethylfluorescein diacetate was from Invitrogen (Carlsbad, CA, USA). The human ovarian cancer cell lines SKOV3ip1 (first described by Janet Price (Yu et al., 1992; Brader et al., 1997) and HeyA8 were from Gordon B. Mills (MD Anderson Cancer Center, Houston, TX, USA). The function-blocking antibodies against human a 5 b 1 -integrin (M200, referred to as Hu a 5 Ab), mouse a 5 b 1 -integrin (339.1, referred to as Murine a 5 Ab) and Avastin (Genentech) were provided by Facet Biotech Corp (Redwood City, CA, USA). Non-specific human or mouse IgG was from Chrome Pure, Jackson ImmunoResearch, West Grove, PA, USA.
Materials and methods

Reagents and cell lines
Mouse orthotopic xenograft model of ovarian cancer
The xenograft model was described previously (Sawada et al., 2007 . Briefly, HeyA8 or SKOV3ip1 cells (1 Â 10 6 ) were injected intraperitoneally into 6-week old, female, athymic nude mice. On days 3 (HeyA8) and 8 (SKOV3ip1) after injection, by which time the cells had metastasized and visible metastatic tumors had developed, mice were randomized into treatment groups. All antibodies were injected intraperitoneally at a dose of 10 mg/kg, twice a week. Treatment continued until day 20 for HeyA8 and day 35 for SKOV3ip1 models.
Immunohistochemistry
Immunohistochemical studies were performed by using 5 mm thick formalin-fixed deparaffinized sections as previously described . Xenograft tumor tissue was probed with anti-CD31 antibody (1:100), anti-Ki-67 (1:300), anti-p-c- Met Y 1230 Met Y , 1234 Met Y , 1235 (1:50) and anti-p-FAK Y 397 (1:200). Specimens of normal human omentum that were obtained from patients undergoing surgery for benign conditions were stained for fibronectin (1:600), collagen IV (1:50, laminin (1:50)) or vitronectin antibody (1:500).
Western blot analysis
Cells or tumor tissues were lysed, proteins were separated by 4-20% gradient SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose, and probed with the respective primary and secondary antibodies .
Immunoprecipitation
Cell lysates were precleared with protein A/G agarose beads and incubated with anti-a 5 -integrin, c-Met or Src antibodies, followed by protein A/G agarose beads . The beads were then spun down and washed, boiled for 5 min in SDS-polyacrylamide gel electrophoresis-gel loading buffer, chilled and spun down. Equal amounts of the supernatant were then separated by 4-20% SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane, probed for coimmunoprecipitation of c-Met, a 5 -integrin or Src antibodies and later stripped and reprobed for the immunoprecipitated protein.
Immunofluorescence imaging
HeyA8 cells were plated in serum-free medium on fibronectincoated cover slips (5 ug/ml) and allowed to attach overnight. Thereafter, the cells were fixed with 4% paraformaldehyde in phosphate buffered saline, permeabilized with 0.1% Triton X-100 and probed with rabbit anti-a 5 -integrin and mouse anti-cMet antibodies at 4 1C overnight (1:200). The samples were washed and incubated with Alexa Fluor 594-labeled goat antirabbit antibody (1:1000) and fluorescein-labeled goat antimouse antibody (1:1000), mounted with Prolong Gold (Invitrogen) and analyzed using a Leica SP2 laser scanning confocal microscope (Leica, Wetzlar, Germany).
Transient transfection
HeyA8 cells were transfected with 30 nM siRNA against a 5 -integrin (Ambion, Austin, TX, USA) or against c-Met using Lipofectamine 2000 transfection reagent (Invitrogen). The plasmids for the constitutively activated FAK (CD2FAK), CD2FAK with a mutation at the autophosphorylation site (CD2FAK Y397F) and the control vector (CD2) not expressing FAK were a kind gift from Dr Alan Horwitz, University of Virginia School of Medicine. HeyA8 cells or SKOV3ip1 cells were seeded in 6-well plates and transfected with 1 mg DNA using Fugene6 transfection reagent (Roche, Basel, Matrigel invasion assay Cellular invasion was assayed in vitro as described previously using matrigel coated Boyden chambers (BD Falcon, Franklin Lakes, NJ, USA) . Wherever applicable, the human a 5 b 1 -integrin antibody or control IgG (25 mg/ml) was added to the top chamber. Cells were fixed with 4% paraformaldehyde after 24 h, stained with giemsa and enumerated. Experiments were performed in triplicate and 5 fields ( Â 200 magnification) per filter counted.
Adhesion assay
Cellular adhesion was assayed in vitro as described previously . Briefly, ovarian cancer cells were fluorescently labeled with 10 mM 5-chloromethylfluorescein diacetate and treated with the human a 5 b 1 -integrin antibody or control IgG (25 mg/ml), and plated in a 96-well plate precoated with fibronectin (5 mg/ml). Adherent cells were quantified by measuring fluorescent intensity (excitation, 490 nm; emission, 520 nm).
Statistical analysis
Data analysis was done by unpaired, two-tailed Student's t-test assuming equal variance of the test and the control populations.
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